2月26日 - ** 疫苗生产商NovavaxNVAX.O股价盘前上涨4.4%至9.9美元
** 该公司上调了2026年的收入预期；现在预计 (link) 调整后的收入为2.3亿至2.7亿美元，而此前为1.85亿至2.05亿美元。
** 预测不包括与赛诺菲SASY.PA合作的销售额和特许权使用费
** NVAX 公布第四季度盈利 1800 万美元，去年同期亏损 8100 万美元。
** 根据LSEG汇编的数据，第四季度营收为1.47亿美元，超过分析师平均预期的7884万美元。
** 今年以来股价上涨 41%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.